MACS® Immuno-Oncology Days

13th Miltenyi Biotec Scientific Days 

Mobilizing specific T cells against cancer

Friday, July 5, 2019 
08:30 a.m.—05:00 p.m. 
Cité Internationale Universitaire de Paris 
17 Boulevard Jourdan, 75014, Paris 


08:30 a.m.Introduction and opening
Guido Kroemer, Centre de Recherche des Cordeliers, France
Laurence Zitvogel, Institut Gustave Roussy, France
08:45 a.m.Agonism T cells through ICOS agonist antibodies
Axel Hoos, GlaxoSmithKline, USA
09:30 a.m.Stem-like qualities of anti-tumor immune responses upon adoptive transfer
Enrico Lugli, Humanitas Clinical and Research Center, Italy
10:00 a.m.Using automation and innovation to fuel advanced T cell therapies
Andrew Kaiser, Miltenyi Biotec, Germany
10:30 a.m.Coffee break
11:00 a.m.Precision engineering to advance adoptive T cell therapies
Justin Eyquem, University of California, San Francisco, USA
11:30 a.m.Epigenetic control of tumor infiltrating T cells
Sebastian Amigorena, Institut Curie, France
12:00 p.m.Lunch break
02:00 p.m.Use of bispecific antibodies to enable adoptive T cell therapy of cancer
Sebastian Kobold, Klinikum der Universität München, Germany
02:30 p.m.Safe redirection of T lymphocytes against HER2-positive tumors
Joaquin Arribas, Vall d’Hebron Institute of Oncology, Spain
03:00 p.m.Engineered bispecific antibodies for combination cancer immunotherapy
Christian Klein, Roche Innovation Center, Switzerland
03:30 p.m.Coffee break
04:00 p.m.Arming the prime time killer: an immune engineering perspective
Jogender Tushir-Singh, University of Virginia, USA
04:30 p.m.Development of novel fully human bispecific antibodies for oncology
Dimitris Skokos, Regeneron Pharmaceuticals, USA

Attendance is free of charge. 

Please register online here.


or call +33 1 56 98 16 16